Zolbetuximab-Vyloy was developed by which company

Zolbetuximab-Vyloy is a monoclonal antibody targeting Claudin 18.2 (CLDN18.2) developed by Japanese pharmaceutical giant Astellas Pharma. This drug is mainly targeted at patients with advanced gastric cancer and gastroesophageal junction adenocarcinoma (GEJ adenocarcinoma) and is a new generation of precision targeted therapy drugs. Astellas is a world-renowned pharmaceutical company that has long been focused on the fields of oncology, urinary system diseases and immunology, and is committed to developing innovative therapies. Zotuximab is one of its important layouts in tumor immunotherapy.

The drug was first developed by Ganymed Pharmaceuticals, which was later acquired by Astellas, and the research and development work of zotuximab was subsequently transferred to Astellas. This drug is aimed at gastric cancer patients with high expression of CLDN18.2. It uses targeted monoclonal antibody technology to specifically bind to the CLDN18.2 protein on the surface of cancer cells, thereby triggering the immune system to attack cancer cells. Research data shows that zotuximab has demonstrated good anti-tumor activity in clinical trials, especially in the SPOTLIGHT and GLOW phase III clinical trials, when used in combination with standard chemotherapy, it can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients.

Currently, Astellas is actively promoting the global marketing approval of zotuximab, including the Chinese market. As an innovative targeted tumor therapy drug, this drug is expected to become a new option for the treatment of gastric cancer, especially for CLDN18.2-positive patients, bringing them more precise and efficient treatment options. Overall, the advent of zotuximab is an important milestone in Astellas' innovation path and also provides a new direction for the development of the field of tumor treatment.

Reference: https://en.wikipedia.org/wiki/Zolbetuximab